Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis

Documenti analoghi

• Frequency and Nature of Generic “Design Around” of Brand‐Name Patents in the United States
  di: Janet Freilich, et al.
  Pubblicazione: (2025)
• Background Factors Contributing to Safety Warning Discordance in the Initial Labeling of New Drugs in Japan, the United States, and the European Union
  di: Koichi Fukuda, et al.
  Pubblicazione: (2024)
• Comparative Analysis of Post‐Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023
  di: Diana Mandslay, et al.
  Pubblicazione: (2024)
• Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight
  di: Jae Hyeon Yu, et al.
  Pubblicazione: (2024)
• Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
  di: Minji Kim, et al.
  Pubblicazione: (2026)